Quantification of Phosphorylated Alpha-synuclein in Cutaneous Biopsies as a Prospective Biomarker in Parkinson's Disease
Status: Recruiting
Location: See all (17) locations...
Study Type: Observational
SUMMARY
This study aims to assess the levels of phosphorylated alpha-synuclein (P-SYN) in patients with Parkinson's disease and REM Behavior Disorder using a minimally invasive skin punch biopsy. It seeks to understand the natural progression of P-SYN deposition over time to explore the potential of P-SYN quantification as a biomarker for disease progression.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 50
Maximum Age: 100
Healthy Volunteers: f
View:
• Male and female 50 to 100 years of age
• Clinical confirmed diagnosis of Parkinson\'s disease or REM Sleep Behavior
Locations
United States
Arizona
CND Life Sciences
RECRUITING
Scottsdale
Movement Disorders Center of Arizona
RECRUITING
Scottsdale
California
Parkinson's Research Centers of America - Orange County
RECRUITING
Aliso Viejo
Cedars Sinai
RECRUITING
Los Angeles
Parkinson's Research Centers of America - Palo Alto
RECRUITING
Palo Alto
Colorado
University of Colorado
RECRUITING
Aurora
Florida
Aventura Neurologic Associates, LLC
RECRUITING
Aventura
Parkinson's Disease and Movement Disorders Center - Boca Raton
RECRUITING
Boca Raton
Georgia
Atlanta NeuroScience Institute ANI
RECRUITING
Atlanta
Kansas
Parkinson's Disease and Movement Disorders Center at KUMC
RECRUITING
Kansas City
Kentucky
Neurology Multidisciplinary Clinic at Norton Healthcare
RECRUITING
Louisville
Massachusetts
Boston Neuro Research Center
RECRUITING
Boston
Maryland
MedStar Montgomery Medical Center
RECRUITING
Olney
New York
Parkinson's Research Centers of America - Long Island
RECRUITING
Commack
University of Rochester
RECRUITING
Rochester
Tennessee
Veracity Neuroscience LLC
ACTIVE_NOT_RECRUITING
Memphis
Texas
UT Health San Antonio
RECRUITING
San Antonio
Contact Information
Primary
Clinical Research
clinicalresearch@cndlifesciences.com
480-569-2902
Time Frame
Start Date: 2024-12-17
Estimated Completion Date: 2026-04
Participants
Target number of participants: 100
Related Therapeutic Areas
Sponsors
Leads: CND Life Sciences
Collaborators: Michael J. Fox Foundation for Parkinson's Research